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Recent evidence has suggested that signals
other than those from Toll-like receptors
(TLRs) could contribute to the elicitation of anti-
gen-specific immunity. Therefore, we examined
the role of the Nod-like receptor (NLR) family
member, Nod1, in the generation of adaptive
immune responses. Our findings show that
innate immune sensing of peptidoglycan by
Nod1 is key for priming antigen-specific T cell
immunity and subsequent antibody responses
in vivo. Nod1 stimulation alone was sufficient
to drive antigen-specific immunity with a pre-
dominant Th2 polarization profile. In conjunc-
tion with TLR stimulation, however, Nod1 trig-
gering was required to instruct the onset of
Th1 and Th2 as well as Th17 immune pathways.
Cells outside of the hematopoietic lineage pro-
vided the early signals necessary to orchestrate
the development of Nod1-dependent immune
responses. These findings highlight Nod1 as
a key innate immune trigger in the local tissue
microenvironment that drives the development
of adaptive immunity.
INTRODUCTION
Engagement of pattern recognition molecules (PRMs) with
their microbial ligands induces specific downstream sig-
naling events and thereby provides immediate first-line
protection of the host from invading pathogens. This is
mediated by a number of innate systems including the
activation of the complement pathway, phagocytosis of
microbes, the release of direct antimicrobial mediators,
and the production of cytokines, chemokines, and inter-ferons that collectively instruct mechanisms to combat
infection. Several PRMs have been characterized in a
number of different hosts, such as pathogen-resistance
proteins (R-proteins) in plants, the Drosophila Toll protein,
and Toll-like receptors (TLRs) in Caenorhabditis elegans
and mammals. During the last decade, many microbial
motifs sensed by TLRs have been deciphered, and their
impact on the induction of first-line host responses has
been demonstrated (Iwasaki and Medzhitov, 2004; Kawai
and Akira, 2005).
Depending on the cell type and molecule, the localiza-
tion of TLRs is restricted to the cell surface or specialized
cell organelles, especially the endolysosomal compart-
ment. Conversely, bacteria use a variety of strategies to
escape the endolysosomal compartment (Cossart and
Sansonetti, 2004), which suggests that the cytosolic loca-
tion of a pathogen may provide optimal protection from
immune recognition and response. Recent findings now
indicate that vertebrates have also evolved strategies to
recognize these bacteria inside the cell via members of
the Nod-like receptor (NLR) protein family (Fritz et al.,
2006; Inohara et al., 2004; Ting and Davis, 2005), Nod1
and Nod2, in particular, representing a means of cytosolic
surveillance. The relevance of Nod proteins for antimicro-
bial immunity has recently been demonstrated by studies
with Nod-deficient animals. Nod1-deficient mice have
a higher susceptibility toward Helicobacter pylori infection
(Viala et al., 2004), and diminished clearance of Listeria
monocytogenes is observed in Nod2-deficient mice
(Kobayashi et al., 2005). Increasingly, studies implicate
Nod1 and/or Nod2 in the antimicrobial response to a vari-
ety of different bacteria through the recognition of distinct
peptidoglycan (PGN) motifs, leading to subsequent down-
stream signaling events by activation of transcription
factors such as nuclear factor kB (NF-kB) and activator
protein (AP)-1 (Fritz et al., 2006; Kufer et al., 2005).
The concept that successful antigen-specific immunity
is dependent on innate immune recognition systems has
been supported by the fact that PRM-mediated detectionImmunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 445
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Nod1 Instructs Antigen-Specific Immunityof microbe-associated molecular patterns (MAMPs), such
as stimulation of TLRs by their cognate agonists, provides
signals for priming antigen-specific Th1 and Th2 immune
responses (Dabbagh and Lewis, 2003; Johnson et al.,
2003). In addition, animals deficient in MyD88, a common
TLR signaling protein, have altered antigen-specific T and
B cell immunity (Pasare and Medzhitov, 2005; Schnare
et al., 2001). More recently, however, these findings
were challenged because mice genetically deficient in
both MyD88 and TRIF, and thereby completely lacking
the ability to signal downstream of TLRs (Hoebe et al.,
2003; Janssen et al., 2006; Yamamoto et al., 2003), mount
unaltered antibody responses to T cell-dependent anti-
gens, given in the context of adjuvant preparations (Gavin
et al., 2006; Nemazee et al., 2006). These intriguing find-
ings suggest, therefore, that innate immune recognition
systems other than TLRs contribute to the onset of
antigen-specific immune responses (Wickelgren, 2006).
Following this idea, we set out to investigate the instruc-
tive potential of Nod1-mediated PGN recognition on
priming of adaptive immune responses.
Our findings uncover a key role for Nod1 in priming
antigen-specific responses in vivo. By using the common
adjuvant, complete Freund’s adjuvant (CFA), in typical im-
munization experiments with T cell-dependent antigen,
we show the critical role of Nod1 triggering, acting in syn-
ergy with TLRs, to prime Th1 as well as T helper 17 cell
(Th17) immune pathways in vivo. These results are further
highlighted by the observation that the antigen-specific
response to H. pylori, a bacterium that was shown to trig-
ger Nod1 signaling in gastric epithelial cells (ECs) (Viala
et al., 2004), is diminished in Nod1-deficient animals.
When acting alone, Nod1 agonist elicits priming of anti-
gen-specific T and B cell immunity with a predominant
Th2 cell polarization profile. Even though dendritic cells
(DCs) are thought to be key players in integrating microbial
and antigen signals to instruct adaptive immune re-
sponses, wild-type DCs and hematopoietic cells in gen-
eral could not compensate for Nod1 deficiency as re-
vealed by reconstitution experiments. Taken together,
these findings highlight Nod1 as a key component of in-
nate immune signaling responsible for priming of anti-
gen-specific responses in vivo. Consistent with recent
findings (Kapsenberg, 2003; Stetson et al., 2004), our re-
sults also underscore the importance of the tissue micro-
environment, which includes nonhematopoietic cells such
as ECs, fibroblasts, and stromal cells, in conditioning DCs
and thereby impacting on the generation of the antigen-
specific adaptive immune response.
RESULTS
Nod1 Is Required for Optimal Generation
of T Cell Responses
To analyze the role of Nod1-mediated PGN recognition
for the onset of adaptive immunity, we first applied the
standard immunopotentiator CFA, containing heat-killed
Mycobacteria, which are sensed by TLRs as well as
Nod1 (see Figures S1A–S1C in the Supplemental Data446 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.available online). As expected in wild-type (WT) animals,
immunizations with the T cell-dependent antigen ovalbu-
min (OVA) and CFA led to a mixed response, inducing
antigen-specific T cells producing IFN-g, IL-4, and IL-17A.
In contrast, markedly altered Ag-specific immunity was
observed in spleen and draining lymph nodes of Nod1-
deficient mice after immunization with CFA (Figures 1A–
1C). Intracellular FACS and ELISPOT analysis revealed
a significant reduction of OVA-specific IFN-g-producing
CD3+CD4+ and CD3+CD8+ T cells in Nod1-deficient
mice (Figures 1A and 1B). In addition, reduced numbers
of IL-4-producing T cells upon restimulation with OVA
protein, OVA(257-264), or OVA(265-280) were observed
in Nod1-deficient mice after immunization with OVA and
CFA (Figure 1B), demonstrating that the elicitation of anti-
gen-specific IFN-g- and IL-4-producing CD4+ and CD8+ T
cells is severely diminished in Nod1-deficient animals.
Moreover, markedly less IFN-g and IL-17A was found in
supernatants from splenocytes and cells of draining lymph
nodes restimulated with OVA or OVA(265-280) of Nod1-
deficient animals (Figures 1B and 1C), indicating a defect
in priming of CD4+ Th17 cells. Taken together, these
results revealed that the potent CFA-induced adjuvant
effect mediated by mycobacterial cell-wall constituents
required Nod1-mediated PGN recognition to instruct the
onset of Th1 and Th2 as well as Th17 immune pathways.
Optimal Antibody Responses Require
Nod1 Triggering
To test whether the altered T cell priming correlated with
impaired B cell immunity, we determined the antigen-
specific antibody production in WT and Nod1-deficient
mice after subcutaneous immunizations with OVA emulsi-
fied in CFA. Animals immunized with OVA and CFA
showed that Nod1-deficient mice produced markedly
lower amounts of OVA-specific antibodies than the WT
counterparts. Although slightly less antigen-specific IgG1
was observed, the amount of IgG2b, IgG2c, and IgG3
were found to be significantly lower in Nod1-deficient
animals (Figure 2B), demonstrating that Nod1-mediated
PGN recognition of mycobacteria present in CFA is critical
for the elicitation of antigen-specific T and B cell immunity.
Importantly, Nod deficiency did not impact on the general
ability of the mice to prime adaptive immune responses,
as shown by the fact that immunizations with OVA in the
sole oil-in-water emulsion incomplete Freund’s adjuvant
(IFA) led to similar amounts of antigen-specific IgG1,
IgG2b, IgG2c, and IgG3 as WT mice (Figure 2A). Similar
results were obtained by adsorbing OVA to aluminium
hydroxide (data not shown).
Because we demonstrated that Nod1-deficient mice
have a higher susceptibility toward H. pylori infection
(Viala et al., 2004), we hypothesized that the altered bac-
terial clearance in these mice, at least in part, might result
from a diminished antigen-specific response. WT and
Nod1-deficient mice were challenged orally with H. pylori,
and sera were collected 1 month after infection. Analysis
of the antibody response of mice toH. pylori urease, a ma-
jor protein of the bacterium, revealed equivalent amounts
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Nod1 Instructs Antigen-Specific ImmunityFigure 1. Altered Antigen-Specific T Cell Responses in Nod1-Deficient Mice Immunized with CFA
Immunizations of wild-type (+/+) and Nod1-deficient mice were carried out with ovalbumin (OVA) or OVA emulsified in complete Freund’s adjuvant
(CFA). On day 10 after each immunization, pools of splenocytes (A and B) or draining lymph nodes (C) from immunization groups (n = 4) were restimu-
lated with medium as control, OVA, an MHC class I-restricted (H-2Kb, OVA(257-264)) or an MHC class II-restricted (I-Ab, OVA(265-280)) epitope
derived from OVA.
(A) The frequencies of Ag-specific CD3+CD4+ and CD3+CD8+ T cells producing IFN-g after restimulation with OVA protein were determined by
intracellular FACS analysis. The percentages of gated IFN-g-positive cells are indicated. Data shown are representative of two independent exper-
iments. A representative experiment is shown.
(B) The numbers of Ag-specific CD4+ and CD8+ T cells producing IFN-g or IL-4 per million splenocytes were determined by ELISPOT analysis, and
production of IL-17A in supernatants was determined by ELISA. Data shown are representative of three independent experiments. The mean ± standard
deviation of a representative experiment is given. The asterisk indicates a significant difference (p < 0.05).
(C) Ag-specific IFN-g and IL-17A production of total draining lymph node cells from immunized mice was analyzed by ELISA. The mean ± standard
deviation of triplicates is given.of IgG1 but markedly diminished IgG2c titers in Nod1-
deficient animals compared to WT mice, indicating a
diminished type 1 immune response (Figure 2C) in Nod1-
deficient animals. Taken together, these data indicate that
in the context of bacterial challenge, Nod1-mediated PGN
recognition is critical for instructing adaptive immune
responses, which likely contribute to successful bacterial
clearance from the infected host.
Induction of Adaptive Immunity by Nod1-Specific
Stimulation
Mycobacterial extracts of CFA as well H. pylori are recog-
nized by multiple innate recognition systems including
TLRs and Nod1. Thus, to investigate how Nod1-mediated
PGN sensing elicits priming of antigen-specific immunity,
we next tested whether Nod1 stimulation alone is able to
prime adaptive immunity in vivo. WT and Nod1-deficient
mice were immunized subcutaneously with the Nod1-specific agonist FK156 in conjunction with OVA. We
ascertained the purity of all compounds used for immuni-
zation experiments to ensure that the observed responses
are solely due to specific stimulation of Nod1 (Figures
S2A–S2F). Compared to the effect of immunizations with
OVA only, WT mice given a mixture of OVA and FK156
elicited markedly higher numbers of IL-4- and IL-5-
producing CD4+ T cells upon restimulation with OVA
protein or OVA(265-280) (Figure 3A). Interestingly, stimu-
lation with OVA(257-264) did not yield substantial num-
bers of cytokine-producing CD8+ T cells over controls.
Moreover, immunizations with OVA and the Nod2-specific
agonist muramyl-dipeptide (MDP) or OVA and FK156,
respectively, did not induce antigen-specific CD4+ and
CD8+ T lymphocytes producing IFN-g or IL-17A (data
not shown). Comparable results were obtained when
animals were immunized intraperitoneally (Figure 3B). As
for priming of antigen-specific T cells, we observed thatImmunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 447
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Nod1 Instructs Antigen-Specific ImmunityFigure 2. Altered Antigen-Specific Immunoglobulin Production in Nod1-Deficient Mice upon Immunization with CFA and Bacterial
Infection
Wild-type (+/+, represented by filled circles) and Nod1-deficient (/, represented by empty circles) mice were immunized with ovalbumin (OVA) or
OVA emulsified in incomplete Freund’s adjuvant (IFA) (A) or complete Freund’s adjuvant (CFA) (B), or infected with H. pylori (C). Serum from single
mice was taken on day 26 after immunization or infection, and Ag-specific IgG1, IgG2b, IgG2c, and IgG3 production was analyzed by ELISA. The
bar represents the mean of each cohort (n = 4–6). The asterisk indicates a significant difference (p < 0.05).in WT mice, OVA-specific immunoglobulins (Ig) were
induced after immunizations with FK156. Nod1-deficient
animals displayed a severe deficiency in the production
of antigen-specific IgG1, which was the predominant iso-
type induced (Figure 3C). Although a second injection of
WT animals with OVA and FK156 further enhanced the
antigen-specific antibody production, this mixture still
failed to do so in Nod1-deficient mice (Figure 3C), demon-
strating that FK156 elicits priming of a CD4+ T helper cell
immune response with a Th2 polarization profile and sub-
sequent IgG1 production in a Nod1-dependent manner.
By comparing the immunostimulatory capacity of FK156
with the Nod2 agonist MDP, we observed the induction
of similar antigen-specific IL-4- and IL-5-producing T cells
and IgG1 specific for OVA (Figures 3A and 3C), revealing
that the Nod2-mediated T cell priming by MDP remains
unaltered in Nod1-deficient animals. No significant OVA-
specific IgG2b, IgG2c, or IgG3 titers were detected after448 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.prime-boost immunizations with OVA in conjunction with
the Nod1 agonist FK156 or the elicitor of Nod2, MDP
(data not shown), suggesting that both PGN fragments
induce a predominant type 2 immune response. In addi-
tion, it was observed that the adjuvant activity of the
Nod1-specific agonist FK156 remained unaltered in Nod2-
deficient mice (data not shown), indicating that Nod1 and
Nod2 recognize distinct PGN structures for elicitation of
adaptive immune responses.
A detailed analysis of Nod1-deficient mice revealed that
animals were outwardly healthy and that WT and Nod1/
mice displayed equal amounts of basal Ig and IgG iso-
types (Figures S3A and S3B). In addition, FACS analysis
of cells isolated from thymus and spleen showed normal
development of B cells, DCs, CD4+ T cells, and CD8+ T
cells (Figures S3C–S3H). Because Nod1 is also expressed
in T and B cells (Figure S4A), we investigated whether
Nod1 deficiency alters the intrinsic stimulatory potential
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Nod1 Instructs Antigen-Specific ImmunityFigure 3. Impaired Antigen-Specific T
and B Cell Immunity in Nod1-Deficient
Mice Immunized with FK156
Subcutaneous prime-boost (A and C) (day
0 and day 28) or intraperitoneal one-shot im-
munizations (B) of wild-type (+/+, represented
by filled circles) and Nod1-deficient (/, rep-
resented by empty circles) animals with oval-
bumin (OVA) only or in conjunction with MDP
or FK156 were carried out.
(A) On day 10 after immunizations, pools of
splenocytes from immunization groups (n = 4)
were restimulated ex vivo with medium as
control, OVA, an MHC class I-restricted (H-2Kb,
OVA(257-264) or an MHC class II-restricted
(I-Ab, OVA(265-280)) epitope. The frequencies
of OVA-specific CD4+ and CD8+ T cells pro-
ducing IL-4 or IL-5 per million splenocytes
were determined by ELISPOT analysis. Data
shown are representative of three independent
experiments. The mean ± standard deviation
of a representative experiment is given.
(C) Serum of each mouse was taken on day 26
(prime) and day 54 (boost), and OVA-specific
IgG1 production was analyzed by ELISA.
Data shown are representative of three inde-
pendent experiments. The bar represents the
mean of each cohort (n = 3–6). The asterisk
indicates a significant difference (p < 0.05).of T and B cells. In vitro stimulation of naive splenic CD4+
and CD8+ T cell as well as CD19+ B cells revealed a normal
proliferative response of Nod1-deficient cells (Figures S4B
and S4C). Moreover, comparable amounts of IFN-g, IL-2,
IL-4, and IL-17A were produced by WT and Nod1-defi-
cient CD4+ T cells (Figure S4D). In addition, no differences
of the homeostatic proliferation potential of T and B cells
(Figure S4E) as well as unaltered expression levels of mat-
uration markers of T cells (data not shown) were observed
by comparing WT and Nod1-deficient animals, indicating
that the altered onset of antigen-specific adaptive immu-
nity in Nod1-deficient mice is not due to intrinsic defects
of T and B cells.
TLRs and Nod1 Synergize to Elicit Adaptive
Immune Responses
The orchestration of the various forms of antigen-specific
immunity is regulated by professional antigen-presenting
cells, predominantly DCs. Their immunoregulatory role in
the infected host relies mainly on sensing specific MAMPs
by receptors including PRMs and/or receptors that bind
mediators that are produced in response to infection,
which collectively initiate and modulate DC function todrive different immune effector arms (Kapsenberg,
2003). Thus, we investigated whether Nod1 deficiency im-
pacts on the capacity to directly activate DCs. We did so
by comparing the stimulatory potential of various defined
MAMPs, including the murine Nod1 elicitor FK156 (Magal-
haes et al., 2005), and various TLR agonists on WT and
Nod1-deficient DCs. The activity of FK156 for IL-1b,
IL-6, TNF-a, and IL-12p40 production by bone marrow-
derived dendritic cells (BMDCs) isolated from WT mice
was found to be completely abolished in cells from
Nod1-deficient animals (Figure 4A). However, FK156
stimulation of BMDCs did not induce the release of IL-10,
IL-12p70, IL-23, TGF-b, KC, MIP-2, or MCP-1 or change
the cell-surface expression of costimulatory molecules
CD80, CD86, and CD40 (data not shown). Equal amounts
of IL-1b, IL-6, IL-10, IL-12p40, IL-12p70, IL-23, TNF-a (Fig-
ures 4B and 4C), as well as TGF-b (data not shown), were
produced when Nod1-deficient or WT BMDCs were
treated with the purified TLR2 agonist Pam3CSK4 or the
TLR4 elicitor LPS. Moreover, TLR2 and TLR4 stimulation
induced similar amounts of cell-surface expression
of costimulatory molecules CD80, CD86, and CD40
on BMDCs from WT and Nod1-deficient mice (dataImmunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 449
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Nod1 Instructs Antigen-Specific ImmunityFigure 4. TLRs and Nod1 Synergize for Dendritic Cell Cytokine Production and NF-kB Signaling
(A–C) Bone marrow-derived dendritic cells were stimulated for 40 hr with FK156 only (A) or combinations of FK156 and Pam3CSK4 or LPS (B and C),
and the amounts of IL-1b, IL-6, IL-10, IL-12p40, IL-12p70, IL-23, and TNF-a in supernatants was determined by ELISA. Data shown are representative
of three independent experiments. The mean ± standard deviation of a representative assay performed in triplicate is shown. The asterisk indicates
a significant difference (p < 0.05).
(D) HEK293T cells were transiently cotransfected with combinations of TLR2 and hNod1 together with a NF-kB-luciferase reporter construct. Agonists
for hNod1 (MtriDAP, 250 nM), TLR2 (Pam3CSK4, 100 nM) were used to analyze the NF-kB-dependent luciferase activation. The fold induction of
NF-kB-dependent luciferase activity over background stimulation showing mean ± standard deviation is given. A representative assay performed
in triplicate is shown. The asterisk indicates a significant difference (p < 0.05).not shown), indicating that Nod1 deletion abolishes
FK156-mediated effects but does not alter the capacity
of TLR agonists to stimulate cytokine release in BMDCs.450 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.In addition, comparable numbers of CD11c+CCR7+ DCs
were found in draining lymph nodes of FK156 (data not
shown) or CFA-injected WT and Nod1-deficient mice
Immunity
Nod1 Instructs Antigen-Specific Immunity(Figure S5). Furthermore, similar cell-surface expression
of the costimulatory molecules CD80, CD86, and CD40
were observed in draining lymph nodes of WT and
Nod1-deficient mice, indicating that Nod1 deficiency
does not alter the migratory capacity of DCs (Figure S5
and data not shown). Interestingly, simultaneous stimula-
tion of BMDCs from WT mice with FK156 and Pam3CSK4
or LPS led to synergistic production of the mediators
IL-1b, IL-6, TNF-a, and IL-12p40 as well as the anti-inflam-
matory cytokine IL-10 (Figures 4B and 4C), whereas no
significant changes for TGF-b were observed (data not
shown). Moreover, costimulation of DCs by FK156 with
Pam3CSK4 or LPS led to a significant increase in the pro-
duction of the Th1 immunity promoting cytokine IL-12p70
(Figure 4C). In addition, synergistic activation by FK156
and LPS was observed for the production of the Th17-pro-
moting cytokine IL-23 (Figure 4C). However, the capacity
of FK156 to cooperate with TLR agonists for enhanced
cytokine production was completely absent in Nod1-defi-
cient animals (Figures 4B and 4C), indicating that the
BMDC potentiating effects of FK156 are abolished in
Nod1-deficient mice.
HEK293T cells cotransfected with Nod1 and TLR2 and
synergistically stimulated by their respective agonists re-
vealed enhanced activation of NF-kB compared to stimu-
lations of Nod1 or TLR2 alone (Figure 4D). This suggests
that cooperative Nod1 and TLR activation enhances sig-
naling through NF-kB, leading to the synergistic produc-
tion of Th1- and Th17-promoting factors such as IL-12
and IL-23. To investigate whether these observations are
of relevance for the initiation and development of adaptive
immunity in vivo, we analyzed the antigen-specific immune
response after coinjections with FK156 and TLR agonists.
When compared to injections with the sole compounds,
simultaneous application of FK156 and LPS lead to a sig-
nificant increase of IL-12p40 into the bloodstream of
animals (Figure 5A). In addition, coinjections of OVA with
Pam3CSK4 and FK156 or LPS and FK156 significantly in-
creased the magnitude of Ag-specific T cells compared
to immunization with single TLR2 or TLR4 agonists (Fig-
ures 5B–5D). Although comparable numbers of OVA-
specific IL-4-producing CD4+ T cells were found, a marked
increase in Ag-specific release of IFN-g and IL-17A was
observed by ELISPOT, ELISA, and intracellular FACS anal-
ysis (Figures 5B–5D), demonstrating that Nod1-mediated
PGN recognition synergizes with TLR agonists to prime
Ag-specific Th1 as well as Th17 immune responses.
Stimulation of Nod1 in Nonhematopoietic Cells
Is Required for Priming Antigen-Specific Immunity
To reveal the mechanisms involved leading to the Th2 im-
mune response induced by sole Nod1 stimulation, we fur-
ther analyzed in vivo the key mediators released upon FK156
injection. We observed that the Nod1-specific agonist
FK156 induced a substantial release of the chemokines
KC and MIP-2 in the bloodstream 2 hr after injection,
which returned nearly to steady-state levels 22 hr after
application (Figures 6A and 6C). Moreover, FK156 in-
duced a marked release of the Th2 immunity promotingchemokine MCP-1 (Figure 6B). This response was strictly
Nod1 dependent, because no significant induction of
cytokines and chemokines was found in Nod1-deficient
mice (Figures 6A–6C), suggesting that the release of these
inflammatory mediators contributes to the elicitation of
Nod1-mediated adaptive immune responses. Because
we observed that Nod1 is not only expressed in ECs and
cells of myeloid origin such as splenic CD11c+ DCs, but
also by CD4+ and CD8+ T cells as well as CD19+ B cells
(Figure S4A), we investigated whether the potent and
fast production of cytokines and chemokines by FK156
was dependent on T and B cells. Injection of FK156 into
Rag1/ animals did not alter the release of KC, MCP-1,
MIP-2 (Figures 6A–6C), IL-6, and TNF-a (data not shown),
indicating that the rapid innate immune response induced
by Nod1-specific PGN sensing is independent of T and
B cells.
To address the mechanisms that cause defective innate
and adaptive immune responses in Nod1-deficient mice,
we performed add-back and reconstitution experiments.
By adding back WT BMDC to Nod1-deficient mice, we
first tested in vivo whether the defect for chemokine
production after FK156 application could be restored.
Although WT animals injected with FK156 were fully capa-
ble of producing MCP-1 (Figure 7A) and KC (data not
shown), a markedly reduced chemokine production was
observed in Nod1-deficient animals receiving WT BMDCs.
In contrast, both WT and Nod1-deficient animals were
capable of producing MCP-1 upon injection of LPS
(Figure 7A). This suggests that in vivo DCs were not
required for the rapid cytokine and chemokine release
induced upon Nod1-mediated PGN sensing. Comparable
results were obtained with bone-marrow reconstitution
experiments. Upon injection of FK156, a rapid release of
MCP-1 (Figure 7B) and KC (data not shown) was observed
in WT animals reconstituted with WT bone marrow but not
in Nod1-deficient animals receiving WT bone marrow.
Importantly, we observed that Nod1-deficient animals
reconstituted with WT bone marrow failed to induce
Nod1-mediated Th2 immune responses. WT animals as
well as WT animals reconstituted with WT bone marrow,
injected with OVA and FK156, elicited antigen-specific
IL-4- and IL-5-producing CD4+ T cells upon restimulation
with OVA protein or OVA(265-280) (Figure 7C). In contrast,
severely diminished T cell frequencies were observed in
Nod1-deficient mice as well as Nod1-deficient animals
reconstituted with WT bone marrow, strongly suggesting
that nonhematopoietic cells are key in triggering the
Nod1-mediated Th2 immune responses.
DISCUSSION
The concept that successful antigen-specific immunity is
instructed by innate immune recognition systems has
been put forward by numerous reports, purporting that
direct stimulation of TLRs by cognate agonists activate
DCs to provide signals for priming adaptive immunity
(Iwasaki and Medzhitov, 2004; Kawai and Akira, 2005).
However, recent evidence points to the idea that innateImmunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 451
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Nod1 Instructs Antigen-Specific ImmunityFigure 5. The Nod1 Agonist FK156 Synergizes with TLR Agonists for Priming of Antigen-Specific Immunity
(A) Blood of wild-type (WT) animals was collected 2 hr after intraperitoneal injection of PBS only, FK156, LPS, or LPS and FK156, and the content of
IL-12p40 in the serum of each mouse was analyzed by ELISA. The bar represents the mean of each cohort (n = 2–3). The asterisk indicates a significant
difference (p < 0.05).
(B–D) WT animals were immunized with ovalbumin (OVA) only, or in conjunction with the indicated stimuli and on day 10 after each immunization,
pools of splenocytes from immunization groups (n = 4) were restimulated with medium as control, OVA, or an MHC class I-restricted (H-2Kb,
OVA(257-264)) or an MHC class II-restricted (I-Ab, OVA(265-280)) epitope derived from OVA.
(B and C) The numbers of Ag-specific CD4+ and CD8+ T cells producing IFN-g or IL-4 per million splenocytes were determined by ELISPOT
analysis (B) and the Ag-specific production of IFN-g and IL-17A in supernatants was determined by ELISA (C). Data shown are representative
of two independent experiments. The mean ± standard deviation of a representative experiment is given. The asterisk indicates a significant differ-
ence (p < 0.05).
(D) The frequencies of Ag-specific CD4+ T cells producing IFN-g or IL-17A after restimulation with OVA protein were determined by intracellular FACS
analysis. The percentages of gated positive cells are indicated. Data shown are representative of two independent experiments.signals distinct from those generated downstream of
TLRs are required for driving the adaptive immune re-
sponse (Gavin et al., 2006; Nemazee et al., 2006). Our
observations now clearly demonstrate that the NLR pro-
tein family member Nod1 contributes to the onset of adap-
tive immunity. Animals deficient in Nod1 mount altered
T and B cell immunity to T cell-dependent antigen given
in the standard immunopotentiator, CFA. Moreover, we
observed that Nod1-mediated PGN recognition is crucial
to instruct antigen-specific immunity upon infection with
a live pathogen. Finally, our study suggests that, in the
context of driving adaptive immunity, Nod1 plays a pre-
dominant role in nonhematopoietic cells.452 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.Our data demonstrate that classical adjuvant prepara-
tions require Nod1-mediated PGN recognition to instruct
the onset of Th1 and Th2 as well as Th17 cell responses.
Immunizations of Nod1-deficient animals with T cell-
dependent antigens given in CFA yielded markedly lower
frequencies of antigen-specific IFN-g-, IL-17A-, and IL-4-
producing CD4+ and CD8+ T cells as well as diminished
IgG1, IgG2b, IgG2c, and IgG3 antibody titers compared
to WT controls. Moreover, H. pylori-infected Nod1-
deficient mice showed diminished antigen-specific titers.
Nod1-mediated PGN recognition, therefore, appears to
be essential for the elicitation of antigen-specific re-
sponses during immunization as well as in bacterial
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Nod1 Instructs Antigen-Specific Immunityinfection, which likely contributes to the successful clear-
ance of pathogens from the infected host.
Our study demonstrates that Nod1-mediated PGN rec-
ognition is essential to cooperate with TLRs for successful
elicitation of adaptive immune responses. Nod1-mediated
PGN sensing markedly enhances TLR-mediated IL-12
release and priming of Th1 and Th17 immune responses
in vivo. Because H. pylori (reviewed in Ferrero, 2005) as
well as the mycobacterial cell-wall constituents used for
the preparation of CFA activate both TLRs and Nod1,
our findings suggest that the severely reduced antigen-
specific T and B cell responses observed in immunizations
with CFA and during infection with H. pylori in Nod1-
deficient animals result from an impaired Nod1-TLR
crosstalk.
Figure 6. Impaired FK156-Mediated Chemokine Production
in Nod1-Deficient Mice
Blood of wild-type (+/+, represented by filled circles), Nod1-deficient
(/, represented by empty circles), and Rag1/ (represented by
filled squares) animals was collected 2 and 22 hr after intraperitoneal
injection of PBS or FK156, and the content of KC (A), MCP-1 (B),
and MIP-2 (C) in the serum of each mouse was analyzed by ELISA.
Data shown are representative of two independent experiments. The
bar represents the mean of each cohort (n = 2–3).In support of these in vivo findings, we demonstrate that
cooperative stimulation of Nod1 and TLRs synergizes for
NF-kB activation and the production of cytokines by
DCs such as IL-12, IL-1b, IL-6, and IL-23, known to be
essential for priming of Th1 and Th17 immune responses
(Bettelli et al., 2006; Langrish et al., 2005; Mangan et al.,
2006; Sutton et al., 2006). In accordance with what has
been reported for DCs of human origin (Fritz et al., 2005;
Tada et al., 2005; van Heel et al., 2005), these data
suggest that the cooperative stimulation of Nod1 and
TLRs to synergize for cytokine production by DCs trans-
lates into enhanced antigen-specific immune responses
in vivo. As reported recently (Ferwerda et al., 2005), we
also observed that the mycobacterial cell-wall constitu-
ents used in the CFA preparation stimulate Nod2. Despite
this, however, our data suggest that in vivo, Nod1 defi-
ciency cannot be overcome by Nod2 stimulation. The
effect of Nod2 deletion on the onset of adaptive immunity
upon immunization with CFA remains to be studied.
Despite the fact that Nod1 stimulation synergizes with
TLRs to prime Th1 and Th17 immune responses, we
observed that the Nod1-specific agonist FK156, when
applied alone, elicits priming of antigen-specific T and B
cell immunity with a predominant Th2 cell polarization pro-
file. The specificity of this response is highlighted by the
observation that Nod1 deficiency does not alter the adju-
vant effect of the Nod2 agonist muramyl dipeptide, which
was shown previously to also generate antigen-specific
Th2 responses (Kobayashi et al., 2005). These findings
underscore the fact that Nod1 and Nod2 recognize distinct
PGN motifs for the induction of innate as well as adaptive
immune responses. By investigating key mediators re-
leased upon specific Nod1 stimulation in vivo, we ob-
served that FK156 induced a substantial release of IL-6,
TNF-a (Magalhaes et al., 2005), as well as the chemokines
KC and MIP-2, known to trigger the recruitment of neutro-
phils (Mantovani et al., 2004). Moreover, we found that
FK156 induced, in a Nod1-dependent manner, a marked
release of the inflammatory chemokine MCP-1, which pro-
motes homing of monocytes and immature DCs to in-
flamed tissues via CCR2 (Mantovani et al., 2004). Several
independent observations describe a predominant role
for MCP-1 in promoting Th2 immunity in both infectious
and allergic disease models (reviewed in Daly and Rollins,
2003). Indeed, the application of MCP-1 to naive T cells in
the presence of antigen drives the differentiation to Th2
cells (Karpus et al., 1997; Lukacs et al., 1997). Moreover,
immunization of MCP-1-deficient mice yields normal levels
of Ag-specific T cells producing IFN-g but markedly alters
levels of Th2 cytokines and reduces IgG1 production (Gu
et al., 2000). In light of these observations, our data sug-
gest that the strong induction of MCP-1 by Nod1-mediated
PGN sensing is key for its ability to prime Ag-specific
immunity with a predominant Th2 polarization profile.
We further aimed to investigate which cell population is
essential for driving Nod1-specific priming of adaptive
immune responses. Surprisingly, even though DCs are
thought to be key players in integrating microbial and
antigen signals to instruct adaptive immune responses,Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 453
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(A) Blood of wild-type (WT) and Nod1-deficient animals who received WT BMDCs (WT)WT andNod1/)WT, respectively) was collected 2 hr after
intraperitoneal injection of PBS, FK156, or LPS, and the content of MCP-1 in the serum of animals was analyzed by ELISA. The mean ± standard
deviation of (n = 2–3) is given. The asterisk indicates a considered significance (p < 0.05).
(B) Wild-type (WT), Nod1-deficient, and bone-marrow chimera animals (WT reconstituted with WT bone-marrow [WT)WT] and Nod1-deficient
reconstituted with WT bone marrow [Nod1/)WT]) were injected intraperitoneally with PBS only or FK156. Blood of animals was collected 2 hr
after intraperitoneal injection, and the content of MCP-1 in the serum of each mouse was analyzed by ELISA. The mean ± standard deviation of
(n = 2–3) is given. The asterisk indicates a considered significance (p < 0.05).
(C) Wild-type (WT), Nod1-deficient, and bone-marrow chimera animals (WT reconstituted with WT bone-marrow [WT)WT] and Nod1-deficient
reconstituted with WT bone marrow [Nod1/)WT]) were injected intraperitoneally OVA only or OVA+FK156. 10 days after immunizations, spleno-
cytes from immunized animals were restimulated ex vivo with medium as control, OVA, an MHC class I-restricted (H-2Kb, OVA(257-264)), or an MHC
class II-restricted (I-Ab, OVA(265-280)) epitope. The frequencies of OVA-specific CD4+ and CD8+ T cells producing IL-4 or IL-5 per million splenocytes
were determined by ELISPOT analysis. The mean ± standard deviation (n = 2–6) is given. The asterisk indicates a considered significance (p < 0.05).WT DCs and hematopoietic cells in general could not
compensate for Nod1 deficiency. Thus, our data clearly
demonstrate that nonhematopoietic cells are key for
Nod1-mediated innate immune recognition of PGN to
instruct antigen-specific Th2 immune responses.
Th2 immunity requires orchestration of innate and
adaptive immune effector mechanisms to protect internal
and external host sites from pathogens and is collectively
described as barrier immunity (Stetson et al., 2004). Th2
cells that stably secrete IL-4 are central in the orchestra-
tion of Th2 immunity (Stetson et al., 2004), involving the
coordinated concentration of activated eosinophils,
mast cells, basophils, and a recently described yet ill-
defined cell population (Fallon et al., 2006; Owyang
et al., 2006). With the propensity for Th2 immune re-
sponses to develop at epithelial barriers, there is the sug-
gestion that the instructive signals and possibly also the454 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.terminal differentiation of Th2 immune responses in vivo
occurs in tissue and that signals that mediate this occur
predominantly in epithelia (Stetson et al., 2004). Although
we cannot exclude the possibility that cells of myeloid or-
igin are required to further translate signals initiated by
Nod1-mediated PGN recognition into a full-blown Th2
response, our data clearly highlight that myeloid cells
are not required to trigger these first signals. Indeed, our
findings point to the idea that innate immune priming by
Nod1 is carried by cells within the tissue microenviron-
ment of the barrier, including nonhematopoietic cells
such as ECs, fibroblasts, and stromal cells. Signals ema-
nating from the barrier are then crucial for the conditioning
of DCs (Rimoldi et al., 2005) and B cells (Xu et al., 2007)
and thereby impact on the generation of the antigen-
specific adaptive immune response. Future experiments
will attempt to delineate which innate and/or adaptive
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barrier signals given upon Nod1-mediated PGN sensing
to instruct antigen-specific Th2 immune responses.
Although ECs provide the first line of defense, bacteria
can gain access across barrier surfaces, where they
encounter DCs, which constitutively sample the tissue
environment (Kelsall and Rescigno, 2004). Thus, multiple
engagements of PRMs on DCs, such as cooperative stim-
ulation by TLRs and Nod1, might play a key role instructing
innate as well as adaptive immune responses, once path-
ogens breach the barrier surface. Hence, based on our
observations demonstrating that Nod1 stimulation signifi-
cantly enhanced Th1 immune responses elicited by TLRs,
we suggest that these two innate immune recognition sys-
tems likely cooperate to fight enteroinvasive bacteria.
Consistent with this idea, it has been shown that IL-17
produced by Th17 cells is implicated in regulating host
defense mechanisms such as recruitment of neutrophils
(Schwarzenberger et al., 2000; Ye et al., 2001) and pro-
duction of antimicrobial peptides (Kao et al., 2004; Liang
et al., 2006). Thus, the marked enhancement of antigen-
specific Th17 immunity by the cooperative activity of
TLRs and Nod1 suggests that these Nod1-mediated
responses constitute an important mechanism to fight
bacterial infection.
Crosstalk between TLRs and NLRs is likely to be crucial
for the balance of immune effector arms, with alterations in
this balance tipping the response toward chronic inflam-
matory disorders and autoimmune diseases. Indeed, a
key role in balancing host immune responses has recently
been assigned to Nod1, because polymorphisms in the
gene encoding this protein were shown to be linked to
increased susceptibility to asthma (Hysi et al., 2005) and
atopic eczema (Weidinger et al., 2005), all of which
represent inflammatory barrier diseases associated with
dysregulated innate and adaptive immune responses.
Taken together, our recent report highlighting the role of
Nod1 in bacterial clearance (Viala et al., 2004) and the
observations provided here stress the importance of
Nod1-mediated PGN recognition in balancing innate as
well as adaptive effector immune responses, and thereby
contributing to host defense. These studies also open up
possible avenues of research in order to explore the spe-
cific role of Nod1 and its crosstalk with TLRs in the control
of specific disease models of inflammatory disorders.
EXPERIMENTAL PROCEDURES
Reagents
Muramyl-dipeptide (MDP, MurNAc-L-Ala-D-isoGln) was purchased
from EMD Biosciences (San Diego, CA). MtriDAP (MurNAc-L-Ala-g-
D-Glu-meso-DAP) was prepared as described previously (Girardin
et al., 2003). Synthetic FK156 (D-lactyl-L-Ala-g-D-Glu-meso-DAP-Gly)
was obtained from Fujisawa Inc. (Japan). Pam3CSK4 was purchased
from EMC Microcollections (Tu¨bingen, Germany), and highly purified
LPS was fromSalmonellaminnesotaR595 from ALEXIS Corp. (Lausen,
Switzerland). Specificity and purity of MDP, MtriDAP, FK156,
Pam3CSK4, and LPS was ensured as previously described (Fritz
et al., 2005; Magalhaes et al., 2005). Human serum albumin (HSA)
and ovalbumin (‘‘OVA-crude’’) were obtained from Sigma-Aldrich
(St. Louis, MO). ‘‘OVA-clean’’ was purchased from Worthington-Biochemical Corporation (Lakewood, NJ). Purified recombinant
H. pylori urease was kindly provided by T.H. Ermak (Acambis, Inc.,
MA). The enzyme was produced in an inactive but fully assembled
form (Lee et al., 1995). Complete Freund’s adjuvant (CFA), incomplete
Freund’s adjuvant (IFA), and desiccated Mycobacterium butyricum
fractions (regrouped as Mycobacterium smegmatis from ATCC strains
19420 and 14468) were obtained from Difco (Detroit, MI). Peptides
were synthesized and purified as previously reported (Fritz et al.,
2004). The following peptides were used: OVA257-264 (H-SIINFEKL-OH,
H2-Kb) and OVA265-280 (H-TEWTSSNVMEERKIKV-OH, I-A
b), both de-
rived from chicken ovalbumin; mTRP-2181-188 (H-VYDFFVWL-OH,
H2-Kb) derived from mouse tyrosinase related protein 2; and
NBVc128-140 (H-TPPAYRPPNAPIL-OH, I-A
b) derived from the core pro-
tein of hepatitis B virus. Expression plasmids for mNod1 and hTLR2
were purchased from InVivogen (San Diego, CA). hNod1-K208R was
generated by site-directed mutagenesis. Expression plasmids for
hNod1 and hNod2 were described previously (Girardin et al., 2003).
Fluorescein-(FITC)-labeled antibodies specific for CD4 (RM4-4),
CD11c (HL3), phycoerythrin-(PE)-labeled anti-CD8a (53-6.7), CD80
(16-10A1), CD86 (16-10A1), and matching isotype controls were pur-
chased from Becton Dickinson (San Diego, CA). Biotin anti-mouse
CCR7 (4B14), allophycocyanin (APC) anti-mouse CD3e (145-2C11),
APC-Cy7 anti-mouse CD8a (53-6.7), matching isotype controls, and
Streptavidin-PE were obtained from eBioscience (San Diego, CA).
Reporter Assay for NF-kB Activation
Human embryonic kidney (HEK) 293T cells (ATCC, Manassas, VA)
were cultured in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 2 mM L-glutamine, 1 mM sodium pyruvate, 13 nones-
sential amino acids (all purchased from Invitrogen, Carlsbad, CA), and
5% fetal calf serum (FCS) (Hyclone, Logan, UT). HEK293T cells were
seeded into 24-well plates at a density of 105 cells/ml, and transfec-
tions with various expression plasmids were carried out as described
previously (Fritz et al., 2005). In brief, cells were transfected overnight
with 1% of FuGENE 6 transfection reagent (Roche Diagnostics, Ger-
many) with 75 ng of the b-galactosidase expression plasmid and
75 ng of the reporter plasmid Igk-luciferase alone or plus the following
vectors: 0.5 ng mNod1, hNod1, hNod1-K208R or hNod2, 50 ng
TLR2. The pcDNA3.1 vector was used to balance the DNA concentra-
tion. Indicated stimuli were added shortly after transfection of cells.
NF-kB-dependent luciferase expression was examined after 20 hr of
incubation and normalized as a ratio to b-galactosidase activity.
Assays were performed in triplicate and data represent at least three
independent experiments. Data show mean ± SEM.
Cytokine Dosage
The concentrations of IFN-g, IL-1b, IL-2, IL-4, IL-6, IL-10, IL-12p40,
IL-12p70, IL-17A, KC, MCP-1, MIP1a, MIP1b, MIP-2, TGF-b, TNF-a
(DuoSet; R&D Systems, Minneapolis, MN), and IL-23 (eBioscience)
in culture supernatants were determined by ELISA as specified by
the manufacturer.
Flow Cytometry
Cells were resuspended in FACS buffer (ice-cold phosphate buffered
saline [PBS] supplemented with 0.1% FCS and 0.2% NaN3 [Sigma-
Aldrich]) and incubated with cell-culture supernatants of the hybrid-
oma 2.4G2 (ATCC; anti-CD16/32 antibody) for 15 min on ice to block
nonspecific staining. Subsequently, specific antibodies or isotype
controls were added and incubated for 30 min. Cells were washed ex-
tensively and resuspended in PBS/0.1% FCS and analyzed by FACS
(FACScan or LSR Benchtop, Becton Dickinson). Dead cells were
excluded based on propidium iodide (Sigma-Aldrich) staining. Data
were analyzed with WinMDI 2.8 or FlowJo software.
Mice, Immunizations, and Infections
All animal experiments were approved by the Animal Ethics Review
Committee of the University of Toronto. C57BL/6 mice were pur-
chased from Janvier (Le Genest, France) or Charles River LaboratoriesImmunity 26, 445–459, April 2007 ª2007 Elsevier Inc. 455
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Laboratories (Bar Harbor, ME). Nod1-deficient mice (Millenium Phar-
maceuticals) have been backcrossed to the seventh generation into
the C57BL/6 background. Mice were submitted to sanitary control
tests and used at the age of 6–14 weeks. All animal experiments
were performed according to local guidelines. WT and Nod1-deficient
mice were tested Helicobacter-free by bacteriological and serological
assays (data not shown).
For the generation of chimeras, recipient mice (WT or Nod1-
deficient) were g-irradiated twice with 5 Gy with a MDS Nordion Gam-
macell 200 irradiator and were reconstituted with 1.5 3 106 T cell-
depleted bone-marrow cells from CD45.1 WT donor mice (6–8 weeks
of age). Donor marrow was depleted of T lymphocytes with CD4 and
CD8 microbeads (Miltenyi Biotech, Bergisch-Gladbach, Germany)
according to the manufacturer’s protocol. At 6–8 weeks after reconsti-
tution, mice were tested for chimerism.
DC add-back experiments were carried out as described previously
(Hanada et al., 2003). In brief, 1.2 3 106 BMDCs from CD45.1 were
resuspended in endotoxin-free PBS and applied intraperitoneally
into WT or Nod1-deficient mice (6–8 weeks of age). Mice were injected
with PBS, 0.1 mmol FK156 or LPS (2 mg) 24 hr after cell transfer.
To determine the ratio of lymphocyte populations, single-cell
suspensions of spleen and thymus of naive mice were prepared and
analyzed by flow cytometry. Basal serum immunglobulin levels were
analyzed by ELISA from blood of naive mice drawn from tail veins.
For analysis of dendritic cell migration, mice were injected subcuta-
neously into the footpads with sterile endotoxin-free PBS (BioWhit-
taker, Apen, Germany) or CFA in a total volume of 100 ml (50 ml per
footpad). Popliteal lymph nodes were removed at indicated time-
points, single-cell suspensions were prepared, and cells were stained
and analyzed by FACS acquiring 2 3 104 cells per sample.
For analysis of cytokine and chemokine responses, animals were
injected intraperotoneally with 0.1 mmol FK156 in endotoxin-free
PBS, LPS (2 mg), a combination of LPS (2 mg) and 0.1 mmol FK156,
or endotoxin-free PBS only in a total volume of 100 ml. At indicated
time points, blood was collected and sera were analyzed by ELISA.
For responses of thymus-dependent antigens, mice were immu-
nized subcutaneously into the left flank or intraperitoneally with a mix-
ture of 100 mg ‘‘OVA-clean’’ and adjuvant (0.1 mmol MDP or FK156,
CFA, or IFA) in a total volume of 100 ml sterile endotoxin-free PBS at
intervals of 28 days. For analysis of the immune response induced
by FK156 in synergy with the TLR agonists Pam3CSK4 or LPS, mice
were immunized with a mixture of 100 mg ovalbumin emulsified in
IFA with or without 0.1 mmol FK156, 25 mg Pam3CSK4, or 25 mg LPS.
10 days after immunizations, pools of spleen cells or draining inguinal
lymph nodes of immunization groups were restimulated ex vivo, and
ELISPOT, intracellular FACS analysis, and ELISA of supernatants
were performed as described below. Blood from tail veins was drawn
26 days after immunization and sera of individual mice were analyzed.
For analysis of homeostatic proliferation of T and B cells in vivo, age-
matched (14 weeks) WT and Nod1-deficient animals were supplied
with BrdU (Sigma, San Diego, CA)-containing drinking water (1 mg/ml)
for 10 days (BrdU-containing drinking water was shielded from light
and replaced every 2 days). BrdU incorporation of spleen and inguinal
lymph node CD3+CD4+, CD3+CD8+, and B220high cells were analyzed
with the FITC BrdU Flow Kit (BD Bioscience, San Diego, CA).
The H. pylori strain B128 was routinely subcultured on blood agar
medium containing 10% horse blood and an antibiotic supplement.
Bacterial suspensions for mouse inoculation were prepared directly
in peptone trypsin broth from 36 hr plate cultures (Viala et al., 2004).
WT and Nod1-deficient mice were each administered a single 0.1 ml
aliquot of these suspensions (equivalent to 108 colony-forming units)
via a teflon catheter as described previously (Ferrero et al., 1998).
The presence of gastric Helicobacter infection in mice was determined
1 month after inoculation, by quantitative culture of gastric tissue
fragments containing both the antrum and corpus and by ELISA of
serum antibodies (Ferrero et al., 1998). Viable counts were performed
by serial dilution of samples in sterile peptone trypsin broth (Ferrero456 Immunity 26, 445–459, April 2007 ª2007 Elsevier Inc.et al., 1998). Diluted samples from gastric biopsy samples were plated
onto blood plates supplemented with bacitracin and nalidixic acid
(Ferrero et al., 1998).
Analysis of T Cell Responses
For intracellular FACS analysis and determination of T cell-derived
cytokines in cell-culture supernatants, freshly isolated splenocytes
from immunized mice were resuspended in complete medium
(DMEM supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate,
13 nonessential amino acids [all purchased from Invitrogen], and 5%
fetal calf serum [FCS; Hyclone]) and plated in 96-well tissue culture
plates at 1 3 106 per well, or in ELISPOT plates at 1 3 106, 5 3 105,
33 105, or 13 105 cells per well in the presence of the indicated stimuli
in triplicate: OVA (50 mg/ml), HSA (50 mg/ml), OVA(257-264) (10 mg/ml),
OVA(265-280) (10 mg/ml), irrelevant H2-Kb (mTRP-2181-188), and I-A
b
(NBVc128-140) restricted peptides (10 mg/ml). As positive controls, con-
canavalin A (10 mg/ml) or PMA/ionomycin (2 3 108 M/7.5 3 107 M)
were applied (all purchased from Sigma-Aldrich). Complete medium
was used as negative control.
Supernatants of tissue-culture plates were collected after 48 hr of
stimulation and analyzed for the presence of IFN-g or IL-17A by ELISA.
Intracellular FACS analysis was performed with the BD Cytofix/
Cytoperm Plus kit (BD Biosciences) by adding the Golgi-Plug after
24 hr of stimulation for 10 hr before proceeding according to the
manufacturer’s protocol. Cells were analyzed by intracellular FACS
after staining with a PE-Cy7-labeled antibody against IFN-g (Becton
Dickinson), a ALEXA-647 antibody specific for IL-17A (eBioscience)
and matching isotype controls.
For analysis by ELISPOT, Multiscreen plates (MAHA S4510 for IFN-g
and MAIP S4510 for IL-4 and IL-5; Millipore, Molsheim, France) were
coated (50 ml/well) with capture antibodies (IFN-g [R4-6A2] at 1 mg/ml;
IL-4 [11B11] at 2 mg/ml; IL-5 [TRFK5] at 2 mg/ml; all purchased from
Becton Dickinson, San Diego, CA) and the assay was carried out as
described (Fritz et al., 2004). In brief, freshly isolated splenocytes
were plated and incubated (IFN-g for 20 hr, IL-4 and IL-5 for 40 hr) at
37C/5% CO2 in triplicate in the presence of the indicated stimuli.
Detection was performed with biotinylated secondary antibodies
(IFN-g [AN18.17.24] at 1 mg/ml, kindly provided by K. Lingnau; IL-4
[BVD6-24G2] at 1 mg/ml; IL-5 [TRFK4] at 1 mg/ml; both obtained from
Becton Dickinson) and horseradish peroxidase-conjugated streptavi-
din (R&D Systems). Spots were visualized with 3,30-Diaminobenzidine
and NiCl2 as a substrate. Plates were analyzed with a BIOREADER
2000 (BioSys, Karben, Germany). Results are expressed as the num-
ber of IFN-g-, IL-4-, or IL-5-producing cells per 1 3 106 splenocytes ±
standard deviation of triplicates. No detectable numbers of cytokine-
producing cells above medium control were observed when
splenocytes were restimulated with a control protein, human serum
albumin, or irrelevant epitopes for MHC class I (H2-Kb) or MHC class
II (I-Ab), ensuring the measurement of the antigen-specific response
in all performed assays.
Analysis of B Cell Responses
Basal levels of Ig isotypes were analyzed by sandwich ELISA on seri-
ally diluted serum samples. Primary antibodies were goat anti-mouse
Ig for total IgG, IgG1, IgG3, IgM, and IgA purchased from Southern
Biotechnologies (Birmingham, AL); and rat anti-mouse IgG2b (R9-91)
obtained from Becton Dickinson. Isotype controls were IgM (11E10),
IgA (S107), IgG1 (15H6), IgG2b (A-1), IgG3 (B10), and total IgG, all pur-
chased from Southern Biotechnologies; biotinylated detection anti-
bodies for total IgG, IgG1, IgG3, IgA, IgM, and IgE were purchased
from Southern Biotechnologies; biotinylated rat anti-mouse IgG2b
(R12-3) was obtained from Becton Dickinson. Inbred mouse strains
with the Igh1-b allele, such as C57BL/6, do not have the gene for
IgG2a and instead express the IgG2c isotype (Martin et al., 1998). Be-
cause commercial IgG2a antibodies crossreact inadequately against
IgG2c, antibodies specific for IgG2c purchased from Bethyl Laborato-
ries Inc. (Montgomery, TX) were used. For analysis of antigen-specific
Ig isotypes, plates were coated with 10 mg/ml OVA in PBS or with
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formed by coating antibodies or antigens to 96-well plates (MaxiSorp;
Nalgene Nunc, Roskilde, Denmark). Bound antibodies of plated sera
samples were detected by sequential incubation with biotinylated sec-
ondary antibodies, horseradish peroxidase-conjugated streptavidin
(R&D Systems), and TMB (Sigma-Aldrich). Reaction was stopped by
acidification with 0.5 M H2SO4 (Sigma-Aldrich) and absorbance was
read at 450 nm.
Bone Marrow-Derived Dendritic Cell Preparations
BMDCs were grown from WT and Nod1/ mice as described previ-
ously (Lutz et al., 1999; Yao et al., 2005). In brief, total bone marrow
cells depleted for red blood cells were seeded at 1.5 3 106 cells per
well in 6-well plates (Falcon, Becton Dickinson Labware, Franklin
Lakes, NJ) in 3 ml of complete culture medium (DMEM supplemented
with 2 mM L-glutamine, 1 mM sodium pyruvate, 13 nonessential
amino acids, 50 mM 2-mercaptoethanol, all purchased from Invitro-
gen), 10% fetal calf serum (FCS; Hyclone), and 10 ng/ml murine
rGM-CSF (R&D Systems). Cells were incubated for 7 days at 37C in
a humidified atmosphere with 5% CO2. On day 7, suspended cells
and loosely adherent cells were harvested and cells were enriched
by magnetic cell sorting with CD11c microbeads (Miltenyi Biotech)
according to the manufacturer’s protocol. CD11c-enriched BMDCs
were seeded in complete culture medium containing 10 ng/ml of
murine rIL-4 (R&D Systems) in 24-well plates at 2 3 106 cells/ml and
used for stimulation.
Lymphocyte Proliferation, Cytokine Production,
and RT-PCR Analysis
Various cell populations from total spleen cells were enriched by
MACS. Dendritic cells were purified with CD11c microbeads while
CD4+ and CD8+ T cells as well as CD19+ B cells depleted for CD11c+
cells were enriched with CD4, CD8, or CD19 mirobeads, respectively.
All microbeads were purchased from Miltenyi Biotech and used ac-
cording to the manufacturer’s protocol. As analyzed by flow cytome-
try, purity of sorted cell populations was above 98%. Purified T cells
or B cells were placed into 96-well plates (43 105/well) and stimulated
with either plate-bound anti-CD33 (145-2C11, BD) and/or anti-CD28
(37.51, BD) or Concanavalin A (Sigma), anti-IgM F(ab’)2 fragment
(Jackson Immuno Research), or LPS (from Salmonella minnesota
R595 from ALEXIS Corp.). Cells were stimulated in triplicate for 72 hr
at indicated concentrations followed by a 12 hr pulse with 0.25 mCi
per well of 3H-thymidine (Sigma). Culture supernatants were assayed
for the production of IL-2, IL-4, IL-17A, and IFN-g by ELISA.
Total RNA was prepared with the RNeasy Mini Kit (Qiagen, Valencia,
CA). Purified RNA was reverse-transcribed with Superscript II RNase H
(Invitrogen) according to the manufacturer’s protocol. The generated
cDNA was amplified by using primers for murine Nod1 (forward primer:
50-AGG AGG CCA ACA GAC GCC-30, reverse primer: 50-CTG ACC
TAG AGG GTA TCG-30), and b-actin (forward primer: 50-GTG GGC
CGC TCT AGG CAC CAA-30, reverse primer: 50-CTC TTT GAT GTC
ACG CAC GAT TTC-30). The cDNA samples were heat-denatured
(95C for 5 min) and then amplified with 35 cycles, each comprising
successive incubations at 95C for 40 s, 55C for 40 s, and 72C for
60 s. A further extension step was done at 72C for 5 min. The ampli-
cons (Nod1, 310 bp; b-actin, 250 bp) were size fractionated onto a 2%
agarose gel and stained with ethidium bromide.
Statistical Analysis
The results are given as mean ± SEM. Statistical analysis was per-
formed with Graphpad Prism software with either a Student’s t test
(Figures 1, 2, and 7) or a Mann-Whitney test. A p value < 0.05 was
considered significant.
Supplemental Data
Five figures and Results are available at http://www.immunity.com/
cgi/content/full/26/4/445/DC1/.ACKNOWLEDGMENTS
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